Factors Promoting the Prolonged Shedding of the Pandemic (H1N1) 2009 Influenza Virus in Patients Treated with Oseltamivir for 5 Days

Overview

Journal Influenza Other Respir Viruses

Publisher Wiley

Specialty Microbiology

Date 2013 Jan 3

PMID 23279949

Citations 20

Authors

Seung M Ryoo

Won Y Kim

Chang H Sohn

Dong W Seo

Bum J Oh

Jae H Lee

Yoon S Lee

Kyoung S Lim

Affiliations

Soon will be listed here.

Abstract

Background: The duration of viral shedding is an important determinant of infectivity and transmissibility and provides vital information for effective infection prevention and control. However, few studies have evaluated viral shedding in patients admitted to hospital with 2009 H1N1 influenza and treated with oseltamivir.

Objective: To determine the incidence of prolonged 2009 H1N1 influenza viral shedding in patients treated for 5 days with oseltamivir and to identify factors that promote prolonged viral shedding.

Methods: This was a prospective, observational cohort study of 173 patients infected with 2009 H1N1 influenza (confirmed by RT-PCR) who were admitted to isolation rooms in the emergency department of our hospital between August 25, 2009 and December 31, 2009. All of the patients were treated according to institutional protocols and received routine follow-up RT-PCR testing after 5 days of oseltamivir therapy. Prolonged viral shedding was defined as a positive follow-up RT-PCR result.

Result: Of the 173 patients in our cohort, 88 (50.8%) showed persistent viral shedding after oseltamivir treatment. Viral shedding was significantly prolonged if antiviral therapy was started ≥ 2 days after symptom onset (OR 2.74, 95% CI 1.29-5.82), if there were major comorbidities (OR 3.07, 95% CI 1.29-7.32), and/or if respiratory symptoms were still present on the day 5 of antiviral treatment (OR 4.13, 95% CI 2.10-8.11).

Conclusions: The presence of major comorbidities, a delay in initiating antiviral treatment, and continuing respiratory symptoms after 5 days of antiviral treatment are associated with prolonged shedding of the 2009 H1N1 influenza virus.

Citing Articles

The immune landscape and viral shedding of Omicron SARS-CoV-2 variants implicate immune escape.

Zhang W, Gai X, Duan Z, Yan C, Huang C, Wu C Front Med (Lausanne). 2025; 11:1478466.

PMID: 39931433 PMC: 11808361. DOI: 10.3389/fmed.2024.1478466.

A robust web-based tool to predict viral shedding in patients with Omicron SARS-CoV-2 variants.

Zhang W, Gai X, Wang B, Duan Z, Zhou Q, Dai L ERJ Open Res. 2024; 10(3).

PMID: 38779041 PMC: 11111115. DOI: 10.1183/23120541.00939-2023.

Median duration and factors that influence the duration of symptom resolution in COVID-19 patients in Ethiopia: A follow-up study involving symptomatic cases.

Abrahim S, Tessema M, Ejeta E, Ahmed M, Defar A, Hussen A Lifestyle Med (Hoboken). 2024; 2(4):e46.

PMID: 38607830 PMC: 8646405. DOI: 10.1002/lim2.46.

The differences in virus shedding time between the Delta variant and original SARS-CoV-2 infected patients.

Li F, Deng J, Xie C, Wang G, Xu M, Wu C Front Public Health. 2023; 11:1132643.

PMID: 37559731 PMC: 10408444. DOI: 10.3389/fpubh.2023.1132643.

Duration of SARS-CoV-2 RNA Shedding Is Significantly Influenced by Disease Severity, Bilateral Pulmonary Infiltrates, Antibiotic Treatment, and Diabetic Status: Consideration for Isolation Period.

Arfijanto M, Asmarawati T, Bramantono B, Rusli M, Rachman B, Mahdi B Pathophysiology. 2023; 30(2):186-198.

PMID: 37218914 PMC: 10204499. DOI: 10.3390/pathophysiology30020016.

References

Perez-Padilla R, Rosa-Zamboni D, Ponce de Leon S, Hernandez M, Quinones-Falconi F, Bautista E . Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico. N Engl J Med. 2009; 361(7):680-9. DOI: 10.1056/NEJMoa0904252. View

Witkop C, Duffy M, Macias E, Gibbons T, Escobar J, Burwell K . Novel Influenza A (H1N1) outbreak at the U.S. Air Force Academy: epidemiology and viral shedding duration. Am J Prev Med. 2009; 38(2):121-6. DOI: 10.1016/j.amepre.2009.10.005. View

Aoki F, Boivin G . Influenza virus shedding: excretion patterns and effects of antiviral treatment. J Clin Virol. 2009; 44(4):255-61. DOI: 10.1016/j.jcv.2009.01.010. View

Leekha S, Zitterkopf N, Espy M, Smith T, Thompson R, Sampathkumar P . Duration of influenza A virus shedding in hospitalized patients and implications for infection control. Infect Control Hosp Epidemiol. 2007; 28(9):1071-6. DOI: 10.1086/520101. View

Na S, Chong Y, Kim M, Kim W, Kim W, Hong S . Duration of viral shedding in patients admitted to hospital with pandemic influenza A/H1N1 2009 infection. J Med Virol. 2010; 83(1):5-9. DOI: 10.1002/jmv.21935. View

Li I, Hung I, To K, Chan K, Wong S, Chan J . The natural viral load profile of patients with pandemic 2009 influenza A(H1N1) and the effect of oseltamivir treatment. Chest. 2010; 137(4):759-68. PMC: 7094292. DOI: 10.1378/chest.09-3072. View

Meschi S, Selleri M, Lalle E, Bordi L, Valli M, Ferraro F . Duration of viral shedding in hospitalized patients infected with pandemic H1N1. BMC Infect Dis. 2011; 11:140. PMC: 3123568. DOI: 10.1186/1471-2334-11-140. View

Ling L, Chow A, Lye D, Tan A, Krishnan P, Cui L . Effects of early oseltamivir therapy on viral shedding in 2009 pandemic influenza A (H1N1) virus infection. Clin Infect Dis. 2010; 50(7):963-9. DOI: 10.1086/651083. View

Choi W, Kim W, Kim S, Oh B, Kim W, Lim K . Clinical characteristics of pneumonia in hospitalized patients with novel influenza A (H1N1) in Korea. Scand J Infect Dis. 2010; 42(4):311-4. DOI: 10.3109/00365540903490026. View

10.

Munster V, de Wit E, van den Brand J, Herfst S, Schrauwen E, Bestebroer T . Pathogenesis and transmission of swine-origin 2009 A(H1N1) influenza virus in ferrets. Science. 2009; 325(5939):481-3. PMC: 4814155. DOI: 10.1126/science.1177127. View

11.

Nicholson K, Aoki F, Osterhaus A, Trottier S, Carewicz O, Mercier C . Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet. 2000; 355(9218):1845-50. DOI: 10.1016/s0140-6736(00)02288-1. View

12.

Ryoo S, Kim W, Sohn C, Seo D, Oh B, Lee J . Factors promoting the prolonged shedding of the pandemic (H1N1) 2009 influenza virus in patients treated with oseltamivir for 5 days. Influenza Other Respir Viruses. 2013; 7(5):833-7. PMC: 5781218. DOI: 10.1111/irv.12065. View

13.

Sato M, Hosoya M, Kato K, Suzuki H . Viral shedding in children with influenza virus infections treated with neuraminidase inhibitors. Pediatr Infect Dis J. 2005; 24(10):931-2. DOI: 10.1097/01.inf.0000180976.81055.ce. View

14.

Cox N, Subbarao K . Influenza. Lancet. 1999; 354(9186):1277-82. DOI: 10.1016/S0140-6736(99)01241-6. View

15.

Eggertson L . Pandemic (H1N1) 2009 lives in some people for at least eight days after symptoms develop. CMAJ. 2009; 181(9):E203. PMC: 2764780. DOI: 10.1503/cmaj.109-3062. View

16.

Itoh Y, Shinya K, Kiso M, Watanabe T, Sakoda Y, Hatta M . In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature. 2009; 460(7258):1021-5. PMC: 2748827. DOI: 10.1038/nature08260. View

17.

Ong A, Chen M, Lin L, Tan A, Nwe N, Barkham T . Improving the clinical diagnosis of influenza--a comparative analysis of new influenza A (H1N1) cases. PLoS One. 2009; 4(12):e8453. PMC: 2795196. DOI: 10.1371/journal.pone.0008453. View

18.

Lee N, Chan P, Hui D, Rainer T, Wong E, Choi K . Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J Infect Dis. 2009; 200(4):492-500. PMC: 7110250. DOI: 10.1086/600383. View

19.

Treanor J, Hayden F, Vrooman P, Barbarash R, Bettis R, Riff D . Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA. 2000; 283(8):1016-24. DOI: 10.1001/jama.283.8.1016. View

20.

Cao B, Li X, Mao Y, Wang J, Lu H, Chen Y . Clinical features of the initial cases of 2009 pandemic influenza A (H1N1) virus infection in China. N Engl J Med. 2009; 361(26):2507-17. DOI: 10.1056/NEJMoa0906612. View